Nanolive imaging confirms success of mesoestetic’s new treatment at the subcellular level

We are happy to see that Nanolive imaging has been used to confirm the success of another new therapy, this time treating melasma. In their latest paper “Depigmenting topical therapy based on a synergistic combination of compounds targeting the key pathways involved in melasma pathophysiology”, mesoestetic’s Biotechnology Unit published Nanolive refractive index images of treated and untreated melanocytes1.

Thanks to the high refractive index values of melanin granules, they could be clearly imaged label-free, using the Nanolive platform. Indeed, the images clearly showed that mesoestetic’s treatment decreased the number of melanin granules in melanocytes, which will translate to decreased pigmentation of melasmas in patient skin.

Nanolive technology has been very useful in order to study the effect of our compounds on melanocytes with high resolution. Live-cell imaging allowed us to see how morphology and melanosomes accumulation changed in real time with the treatment, providing clear evidence of the in vitro efficacy of these compounds.”

Dr. Alfredo Martínez-Gutiérrez

Director of the Biotechnology Unit, mesoestetic

Mesoestetic is a pharmaceutical company leading the development and production of therapies in dermatology and aesthetic medicine. You can read their paper in full here.

CX-A with 96-well plate
References:

(1)  Alfredo, M.-G.; Maribel, P.-M.; Eloy, P.-R.; Susana, G.-E.; Shotze, L. G.; Carmen, G. M. Depigmenting Topical Therapy Based on a Synergistic Combination of Compounds Targeting the Key Pathways Involved in Melasma Pathophysiology. Experimental Dermatology. https://doi.org/10.1111/exd.14752 .

Read our latest news

2023 scientific publications roundup

2023 scientific publications roundup

2023 has been a record year for clients using the Nanolive system in their scientific publications. The number of peer-reviewed publications has continued to increase, and there has been a real growth in groups publishing pre-prints to give a preview of their work....

Subscribe to our newsletter

  • This field is for validation purposes and should be left unchanged.